Structure via PubChem · Public domain (PubChem)
anacetrapib
Sign in to saveAlso known as MK-0859
Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck.
Chemical data
- Formula
- C30H25F10NO3
- Molecular weight
- 637.5 g/mol
- IUPAC name
- (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one
- SMILES
- C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
- InChIKey
- MZZLGJHLQGUVPN-HAWMADMCSA-N
- XLogP
- 8.8
- Polar surface area
- 38.8 Ų
- H-bond donors
- 0
- H-bond acceptors
- 13
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- Hypercholesterolemia, Disorder of lipid metabolism, familial hypercholesterolemia, coronary artery disease
via ChEMBL · EBI
Research
268 papersvia PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 637.167476
Show 3 more facts
- chemical formula
- C₃₀H₂₅F₁₀NO₃
- isomeric SMILES
- C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
- canonical SMILES
- CC1C(OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
4 sectionsContents
- Evidence
- See also
- References
- Further reading
{{chembox | Verifiedfields = changed | verifiedrevid = 444391072 | ImageFile = Anacetrapib.svg | ImageClass = skin-invert-image | ImageSize = 200px | PIN = (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-{[4′-fluoro-2′-methoxy-5′-(propan-2-yl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one | OtherNames = MK-0859 |Section1= |Section2= |Section3= }} Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck.
==Evidence== In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.
Excerpted from Wikipedia’s “anacetrapib” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0